SavedAdd your journal

Journals / Türk Onkoloji Dergisi / 2020 / Cilt: 35 - Sayı: 3

The Effects of Radiotherapy on the Quality of Life in Localized Prostate Cancer Patients

Eda ERDİŞ
Birsen YÜCEL
Gülhan GÜLER AVCI
Pages
242–249
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

IMRT) and RT field (prostate/prostate+seminal vesicle vs. prostate+seminal vesicle+pelviclymph node); EORTC QLQ C-30 and EORTC QLQ PR-25 functional and symptom scales were not differentbetween groups.CONCLUSIONThe RT approach in prostate cancer produced temporary impairment in some scores of QLQ, but allthese scores showed improvement from the first month after RT.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVEThe present study aims to investigate the radiation-related toxicity and its effects on the quality of life inpatients with prostate cancer who received definitive or adjuvant radiotherapy (RT).METHODSEighty-seven localized prostate cancer patients who underwent RT between January 2011 and June 2016were enrolled.
📊
Key Findings & Data:Each patient filled the EORTC QLQC30 and QLQ-PR25 at four different times (startingand ending at RT, one and six months after RT).
💡
Conclusion & Impact:IMRT) and RT field (prostate/prostate+seminal vesicle vs. prostate+seminal vesicle+pelviclymph node); EORTC QLQ C-30 and EORTC QLQ PR-25 functional and symptom scales were not differentbetween groups.CONCLUSIONThe RT approach in prostate cancer produced temporary impairment in some scores of QLQ, but allthese scores showed improvement from the first month after RT.
🔬Design:Survey & Empirical Study
📍Scope:2011 Verileri
⚙️Variables:Domain Parameters

Abstract

OBJECTIVEThe present study aims to investigate the radiation-related toxicity and its effects on the quality of life inpatients with prostate cancer who received definitive or adjuvant radiotherapy (RT).METHODSEighty-seven localized prostate cancer patients who underwent RT between January 2011 and June 2016were enrolled. Each patient filled the EORTC QLQC30 and QLQ-PR25 at four different times (startingand ending at RT, one and six months after RT). EORTC QLQ-C30 questionnaire consists of globalhealth status, five functional (physical, role, cognitive, emotional, social) and nine symptom scales (fatiguenausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties).EORTC QLQ-PR25 consists of two functional (sexual activity and sexual functioning) and foursymptom scales (urinary, bowel, hormonal treatment-related, incontinence aid).RESULTSAccording to the EORTC QLQ-C30 questionnaire, global health status score (p=0.007), emotional score(p=0.016), fatigue (p=0.004) and diarrhea score (p=0.003); according to EORTC QLQPR25 questionnaire,urinary score (p=0.024) were significantly poorer at the end of RT. When patients’ quality of lifequestionnaires were compared concerning treatment type (definitive vs. adjuvant RT), RT technique(3D CRT vs. IMRT) and RT field (prostate/prostate+seminal vesicle vs. prostate+seminal vesicle+pelviclymph node); EORTC QLQ C-30 and EORTC QLQ PR-25 functional and symptom scales were not differentbetween groups.CONCLUSIONThe RT approach in prostate cancer produced temporary impairment in some scores of QLQ, but allthese scores showed improvement from the first month after RT.

🔖

Cite This Article

ERDİŞ, E., YÜCEL, B., AVCI, G. G. (2022). The Effects of Radiotherapy on the Quality of Life in Localized Prostate Cancer Patients. Türk Onkoloji Dergisi, Cilt: 35 - Sayı: 3, 242–249. https://ajindex.com/articles/639194

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Crawford ED. Epidemiology of prostate cancer. Urology 2003;62(6 Suppl 1):3–12
  2. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer [published correction appears in Ann Intern Med. 2008 Jun 3;148(11):888]. Ann Intern Med 2008;148(6):435–48
  3. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360(9327):103–6
  4. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F; European Association of Urology. EAU guidelines on prostate cancer. Eur Urol 2008;53(1):68–80
  5. Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24(13):1990–6
  6. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ Jr, Miller DW, Adams JA, et al. Comparison of conventionaldose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005;294(10):1233–9
  7. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53(5):1097–105
  8. Ling CC, Burman C, Chui CS, Kutcher GJ, Leibel SA, LoSasso T, et al. Conformal radiation treatment of prostate cancer using inversely-planned intensitymodulated photon beams produced with dynamic multileaf collimation. Int J Radiat Oncol Biol Phys 1996;35(4):721–30
  9. Chauvet I, Gaboriaud G, Pontvert D, Zefkili S, Giraud P, Rosenwald JC, et al. Constraints and dosage for prostate cancer patients treated with conformal radiotherapy and intensity modulated radiation therapy. Cancer Radiother 2004;8(6):337–51
  10. Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002;53(5):1111–6
  11. Fayers P, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLO-C30 scoring manual. 3rd ed. Brussels: European Organisation fo